Novo Nordisk A/S
Trump’s Pharmaceutical Tariff Threat Dims as Pfizer Deal Reassures Drugmakers: What It Means for the Industry
On September 30, 2025, President Donald Trump made headlines by shaking hands with Pfizer’s CEO, Albert Bourla, to announce a ... Read more
Eli Lilly’s Obesity Pill Beats Novo Nordisk’s Oral Diabetes Drug in Groundbreaking Head-to-Head Trial
Eli Lilly recently announced exciting results for its new diabetes pill, orforglipron. In a recent study, this medication outperformed Novo ... Read more
Eli Lilly Invests $5 Billion in New Virginia Facility to Enhance Production of Targeted Cancer Drugs and Innovative Treatments
Eli Lilly recently announced an impressive $5 billion investment to build a new manufacturing facility in Goochland County, Virginia. This ... Read more
Unlocking Tariffs: Why Even a Supreme Court Ruling May Not End the Debate
Scott Bessent, the U.S. Treasury Secretary, recently made headlines as he discussed President Trump’s tariffs. His remarks came amid expectations ... Read more
Why Eli Lilly’s Obesity Pill Is Still a Strong Contender Against Novo’s Wegovy Despite Mixed Investor Reactions
Eli Lilly’s stock has been on a rollercoaster ride recently. It took a hit after the company released data on ... Read more
Transform Your Health: FDA Approves Signos’ Revolutionary Glucose Monitoring System for Weight Loss!
The FDA recently approved Signos’ innovative glucose monitoring system designed specifically for weight loss. This marks a significant step for ... Read more
Save Big: Novo Nordisk Slashes Ozempic Prices for Cash-Paying U.S. Diabetes Patients
Novo Nordisk recently announced a significant price drop for Ozempic, their diabetes treatment. This move reflects growing pressure on drugmakers ... Read more
Facing Tough Questions: Why We’re Downgrading Lilly After the Obesity Pill Setback
Eli Lilly recently reported impressive second-quarter earnings, but its stock price took a significant hit—falling over 14%. This decline raises ... Read more
Eli Lilly’s Breakthrough Obesity Pill Achieves 12% Weight Loss in Key Late-Stage Trial: A Game Changer for Weight Management
Eli Lilly recently shared exciting news about its new weight loss pill. In a late-stage trial, the highest dose helped ... Read more
Hims & Hers Shares Drop 10% After Revenue Miss: What Investors Need to Know
Shares of Hims & Hers Health dropped 9% after the company revealed second-quarter results that fell short of Wall Street’s ... Read more
